Main container

Il valore prognostico dei biomarker sierici nell’osteosarcoma

Title
Il valore prognostico dei biomarker sierici nell’osteosarcoma
Code
ProOsteo
Type
Osservazionale
Start Year
2021
Status
Terminato

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more